10-Q: Vaxart Q2 2025: COVID Trial Halted, Nasdaq Delisting

Vaxart reports increased Q2 2025 revenue and reduced net loss, but faces a stop work order on its pivotal COVID-19 vaccine trial and Nasdaq delisting, raising significant going concern doubts.

Summary

• Total revenue for the six months ended June 30, 2025, increased by 606% to $60.606 million, up from $8.582 million in the same period of 2024, primarily driven by government contracts.
• Net loss for the six months ended June 30, 2025, decreased by 25% to $(30.577) million, compared to $(40.883) million in the prior year period.
• Research and development expenses significantly increased by 121% to $80.479 million for the six months ended June 30, 2025, mainly due to increased clinical trial expenses for COVID-19 and norovirus vaccine candidates.
• General and administrative expenses decreased by 22% to $9.665 million for the six months ended June 30, 2025, primarily due to reduced personnel costs and legal/professional fees.
• Cash, cash equivalents, and short-term investments totaled $26.271 million as of June 30, 2025, a decrease from $51.723 million as of December 31, 2024.
• A stop work order was received on August 5, 2025, for the COVID-19 Phase 2b trial under the 2024 ATI-RRPV Contract, halting screening and enrollment, with approximately half of targeted participants enrolled.
• Vaxart received written notification from Nasdaq on July 1, 2025, regarding non-compliance with the minimum bid price requirement, leading to trading suspension on Nasdaq effective July 8, 2025.
• Common stock began trading on the OTCQX Best Market under the symbol VXRT on July 8, 2025.
• A workforce reduction of approximately 21% was implemented in May and June 2025 to decrease operating costs.
• Jeroen Grasman was offered the position of Chief Financial Officer with a tentative start date of May 19, 2025.
• Positive topline results were reported from a Phase 1 clinical trial (Study VXA-109) evaluating second-generation bivalent norovirus vaccine constructs, showing statistically significant increases in NBAA titers.

Sentiment

Score: 2

Explanation: Despite increased revenue and reduced net loss, the severe negative impacts of the stop work order on the primary clinical trial, the Nasdaq delisting, and the explicit 'going concern' warning create a highly unfavorable outlook and significant uncertainty for the company's future operations and financial viability.

Positives

• Total revenue increased significantly by 606% for the six months ended June 30, 2025, primarily due to increased revenue from government contracts.
• Net loss decreased by 25% for the six months ended June 30, 2025, indicating improved financial performance in terms of loss reduction.
• General and administrative expenses decreased by 22% for the six months ended June 30, 2025, reflecting successful cost reduction efforts.
• Positive topline results from the Phase 1 clinical trial (VXA-109) for second-generation bivalent norovirus vaccine constructs showed statistically significant increases in norovirus blocking antibody assay (NBAA) titers (141% for GI.1 and 94% for GII.4).
• Positive topline results from a Phase 1 norovirus bivalent vaccine candidate study in breastfeeding mothers showed significant increases in serum and breast milk antibodies to norovirus.
• The avian influenza vaccine candidate demonstrated 100% protection against death in a robust ferret clade 2.3.4.4b challenge model.
• Altesa Biosciences, Inc., Vaxart's licensee for Vapendavir, announced positive topline results from its Phase 2 study of Vapendavir in chronic obstructive pulmonary disease patients challenged with rhinovirus.

Negatives

• The company's cash, cash equivalents, and short-term investments of $26.3 million as of June 30, 2025, are not sufficient to fund planned operations for 12 months from the filing date.
• A stop work order was issued on August 5, 2025, for the COVID-19 Phase 2b trial under the 2024 ATI-RRPV Contract, halting screening and enrollment, which significantly impacts a major funding source and development program.
• Vaxart received a delisting notification from Nasdaq and its common stock was suspended from trading on Nasdaq effective July 8, 2025, now trading on the OTCQX Best Market.
• The company explicitly states that conditions raise substantial doubt about its ability to continue as a going concern for a period of one year from the issuance date of the financial statements.
• Net cash used in operating activities was $(25.544) million for the six months ended June 30, 2025, indicating continued cash burn.
• The company's cash runway is expected to extend only into the first quarter of 2026, necessitating further capital raises.

Risks

• Significant negative impact on revenues and cash flows if HHS BARDA eliminates, reduces, delays, or objects to funding under the 2024 ATI-RRPV Contract, potentially forcing suspension or termination of the COVID-19 vaccine candidate development.
• Volatility and sporadic trading on the OTCQX Best Market could depress the market price of common stock and make it difficult for stockholders to sell shares.
• The common stock could become subject to the SEC's penny stock rules, which may cause broker-dealers difficulty in completing transactions and limit a stockholder's ability to buy and sell shares.
• There is no assurance that the company will be able to regain listing on Nasdaq or any other national exchange.
• Changes in U.S. and international trade policies may adversely impact business and operating results, including product supply disruption and increased costs.
• Changes in tax laws and regulations, such as the One Big Beautiful Bill Act (OBBBA), or changes in operations may impact the effective tax rate and adversely affect business, financial condition, and operating results.
• Inability to raise additional capital in sufficient amounts or on acceptable terms may require delaying, limiting, reducing, or terminating product development or future commercialization efforts.
• The process of conducting clinical trials is costly and time-consuming, and there is no guarantee of achieving marketing approval for vaccine candidates.
• The probability of successful commercialization is affected by numerous factors, including clinical data, competition, manufacturing capability, and commercial viability.

Future Outlook

Management expects the company's cash runway to extend into the first quarter of 2026. The company is dependent on raising additional capital through equity, debt, or partnerships to fund planned operations. Future plans include conducting a Phase 2b safety and immunogenicity study for the norovirus vaccine candidate as early as the second half of 2025, followed by an End of Phase 2 meeting with the FDA, and potentially a Phase 3 trial as early as 2026, pending funding. Regulatory filing for clinical trials for an HPV vaccine candidate is also planned. The company intends to continue per protocol follow-up for participants already dosed in the COVID-19 Phase 2b trial despite the stop work order.

Management Comments

• "The Company expects to have cash runway into the first quarter of 2026."
• "If the Company is unable to raise additional capital in sufficient amounts or on acceptable terms, management's plans include further reducing or delaying operating expenses."
• "Management is currently evaluating the effect of the stop work order on its liquidity and capital resources."

Industry Context

Vaxart operates in the clinical-stage biotechnology sector, focusing on oral recombinant protein vaccines, a niche area within the broader vaccine industry. The company's reliance on government contracts, particularly from HHS BARDA, highlights the significant role of public funding in advanced vaccine development, especially for pandemic preparedness. The shift to OTCQX trading reflects challenges faced by smaller biotech firms in maintaining Nasdaq listing requirements, while the ongoing development of oral vaccines positions Vaxart as a potential disruptor to traditional injectable vaccines, particularly in areas like COVID-19 and influenza where new variants and administration methods are critical considerations. The positive Phase 2 results for Vapendavir by Altesa Biosciences, a licensed antiviral, also indicate potential for broader impact in infectious disease treatment.

Comparison to Industry Standards

• The H1N1 flu vaccine candidate reduced clinical disease by 39% relative to placebo in a Phase 2 challenge study, compared to Fluzone (a market-leading injectable quadrivalent influenza vaccine) which reduced clinical disease by 27%.

Management Changes

Legal Proceedings

• Himmelberg v. Vaxart, Inc. et al. (Putative Class Action): A partial settlement of $12.0 million was reached, with the company paying $2.0 million and insurers covering the remainder. The court approved the settlement and dismissed claims against the settling defendants in January 2023.
• Roth v. Armistice Capital LLC, et al. (Section 16(b) disgorgement): The district court granted summary judgment to the defendants in March 2024, dismissing all claims. The plaintiff's appeal to the Second Circuit Court of Appeals was re-filed in September 2024 and is currently pending.
• Chan v. Vaxart, Inc. et al. (Opt-Out Action): This lawsuit, nearly identical to an earlier version of the Putative Class Action, has been stayed pending the resolution of the Putative Class Action.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future capital raises, reduced liquidity and potential difficulty in selling shares due to Nasdaq delisting and trading on OTCQX, and the impact of a potential reverse stock split.
• Employees have been impacted by a workforce reduction of approximately 21% in May and June 2025.
• Customers and partners, particularly HHS BARDA, are affected by the stop work order on the COVID-19 Phase 2b trial, which could impact the scope and continuation of government contracts.
• Creditors face increased risk due to the company's explicit 'going concern' warning, indicating substantial doubt about its ability to meet obligations for the next 12 months without additional funding.

Next Steps

• Conduct a Phase 2b safety and immunogenicity study for the second-generation bivalent norovirus vaccine candidate, potentially beginning as early as the second half of 2025, pending partnership or other funding.
• Hold an End of Phase 2 meeting with the FDA for the norovirus program.
• Initiate a Phase 3 trial for the norovirus program as early as 2026, pending a successful End of Phase 2 meeting and funding.
• Work with governments globally to create pandemic monovalent influenza vaccines for emergency use or stockpiling.
• Continue development of the preclinical tri-valent seasonal influenza vaccine candidate.
• Make a regulatory filing to proceed with clinical trials for an HPV vaccine candidate.
• Continue efforts associated with the per protocol follow-up of all participants dosed in the COVID-19 Phase 2b trial under the 2024 ATI-RRPV Contract.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on the company's financial statements.
• Seek stockholder approval at the Special Meeting on September 5, 2025, to effect a reverse stock split to potentially regain Nasdaq compliance.

Key Dates

Recommendation

The combination of a severe 'going concern' warning, the delisting from Nasdaq, and the critical stop work order on the primary COVID-19 vaccine clinical trial creates an extremely high-risk profile. While revenue increased and net loss decreased, these operational and liquidity challenges pose an existential threat to the company's ability to continue its development programs and operations. The immediate future is highly uncertain, making the stock a strong sell for investors.

Keywords

Vaxart, VXRT, Oral Vaccine, Biotechnology, COVID-19 Vaccine, Norovirus Vaccine, Clinical Trials, SEC Filing, 10-Q, BARDA, Nasdaq Delisting, OTCQX, Going Concern, Jeroen Grasman, CFO Appointment, Workforce Reduction